Genelux (GNLX) Depreciation & Amortization (CF) (2022 - 2026)
Genelux (GNLX) recorded quarterly Depreciation & Amortization (CF) of $9000.0 in Q1 2026, down 43.75% quarter-over-quarter from $16000.0 in Q4 2025, and down 84.75% on a YoY basis from $59000.0 in Q1 2025.
Genelux (GNLX) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Genelux's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $9000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 84.75% year-over-year to $9000.0; the TTM figure through Mar 2026 stood at $149000.0 (down 29.05% YoY), while the FY2025 annual figure was $200000.0, down 14.89% from the prior year.
- Depreciation & Amortization (CF) was $9000.0 for Q1 2026 at Genelux, down from $16000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $138000.0 in Q1 2022 to a low of $9000.0 in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $81200.0 across 5 years, with a median of $63000.0 in 2025.
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) jumped 65.79% in 2025, then tumbled 84.75% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $138000.0 in 2022, then tumbled by 31.16% to $95000.0 in 2023, then slumped by 40.0% to $57000.0 in 2024, then slumped by 71.93% to $16000.0 in 2025, then slumped by 43.75% to $9000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $9000.0 (Q1 2026), $16000.0 (Q4 2025), and $61000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,000.00 |
| Mar 31, 2026 | 9,000.00 |
| Dec 31, 2025 | 16,000.00 |
| Dec 31, 2025 | 16,000.00 |
| Sep 30, 2025 | 61,000.00 |
| Sep 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Dec 31, 2023 | 95,000.00 |
| Dec 31, 2023 | 95,000.00 |